nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—STK10—testicular cancer	0.628	1	CbGaD
Bosutinib—Vandetanib—STK10—testicular cancer	0.00317	0.513	CrCbGaD
Bosutinib—Gefitinib—STK10—testicular cancer	0.00301	0.487	CrCbGaD
Bosutinib—STK24—Teniposide—Etoposide—testicular cancer	0.000592	0.152	CbGdCrCtD
Bosutinib—CAMK1D—female gonad—testicular cancer	0.000408	0.00328	CbGeAlD
Bosutinib—STK24—female gonad—testicular cancer	0.000404	0.00324	CbGeAlD
Bosutinib—MAP2K1—gonad—testicular cancer	0.0004	0.00321	CbGeAlD
Bosutinib—STK35—gonad—testicular cancer	0.0004	0.00321	CbGeAlD
Bosutinib—CSK—gonad—testicular cancer	0.000398	0.00319	CbGeAlD
Bosutinib—CSNK1A1—gonad—testicular cancer	0.000395	0.00317	CbGeAlD
Bosutinib—STK25—testis—testicular cancer	0.000394	0.00316	CbGeAlD
Bosutinib—CLK1—gonad—testicular cancer	0.000393	0.00315	CbGeAlD
Bosutinib—EPHA3—testis—testicular cancer	0.000391	0.00314	CbGeAlD
Bosutinib—SRC—embryo—testicular cancer	0.000391	0.00314	CbGeAlD
Bosutinib—TYRO3—female gonad—testicular cancer	0.000391	0.00314	CbGeAlD
Bosutinib—FER—female gonad—testicular cancer	0.000391	0.00314	CbGeAlD
Bosutinib—BMP2K—gonad—testicular cancer	0.000385	0.00309	CbGeAlD
Bosutinib—PLK2—testis—testicular cancer	0.000383	0.00308	CbGeAlD
Bosutinib—LRRK2—gonad—testicular cancer	0.000382	0.00307	CbGeAlD
Bosutinib—YES1—seminal vesicle—testicular cancer	0.000381	0.00306	CbGeAlD
Bosutinib—CASK—Teniposide—Etoposide—testicular cancer	0.000381	0.0981	CbGdCrCtD
Bosutinib—SIK3—testis—testicular cancer	0.000381	0.00306	CbGeAlD
Bosutinib—BTK—female gonad—testicular cancer	0.000381	0.00306	CbGeAlD
Bosutinib—TAOK3—seminal vesicle—testicular cancer	0.000377	0.00302	CbGeAlD
Bosutinib—TNK2—female gonad—testicular cancer	0.000375	0.00301	CbGeAlD
Bosutinib—TLK1—lymph node—testicular cancer	0.000374	0.00301	CbGeAlD
Bosutinib—PTK2B—gonad—testicular cancer	0.000372	0.00299	CbGeAlD
Bosutinib—MAP4K2—female gonad—testicular cancer	0.00037	0.00297	CbGeAlD
Bosutinib—PRKCQ—lymph node—testicular cancer	0.000369	0.00296	CbGeAlD
Bosutinib—STK4—testis—testicular cancer	0.000367	0.00294	CbGeAlD
Bosutinib—STK3—female gonad—testicular cancer	0.000365	0.00293	CbGeAlD
Bosutinib—CAMK1D—testis—testicular cancer	0.000362	0.00291	CbGeAlD
Bosutinib—SIK1—gonad—testicular cancer	0.00036	0.00289	CbGeAlD
Bosutinib—ROCK1—female gonad—testicular cancer	0.00036	0.00289	CbGeAlD
Bosutinib—STK24—testis—testicular cancer	0.000358	0.00287	CbGeAlD
Bosutinib—EPHA4—gonad—testicular cancer	0.000357	0.00286	CbGeAlD
Bosutinib—MAP2K2—gonad—testicular cancer	0.000352	0.00283	CbGeAlD
Bosutinib—ULK3—gonad—testicular cancer	0.000352	0.00283	CbGeAlD
Bosutinib—CSF1R—embryo—testicular cancer	0.000351	0.00282	CbGeAlD
Bosutinib—BMPR2—female gonad—testicular cancer	0.00035	0.00281	CbGeAlD
Bosutinib—MAP3K2—gonad—testicular cancer	0.00035	0.00281	CbGeAlD
Bosutinib—STK36—female gonad—testicular cancer	0.000347	0.00279	CbGeAlD
Bosutinib—EPHB3—female gonad—testicular cancer	0.000347	0.00279	CbGeAlD
Bosutinib—FER—testis—testicular cancer	0.000346	0.00278	CbGeAlD
Bosutinib—ALK—testis—testicular cancer	0.000346	0.00278	CbGeAlD
Bosutinib—TYRO3—testis—testicular cancer	0.000346	0.00278	CbGeAlD
Bosutinib—DSTYK—lymph node—testicular cancer	0.000346	0.00278	CbGeAlD
Bosutinib—BMX—lymph node—testicular cancer	0.000346	0.00278	CbGeAlD
Bosutinib—CLK3—lymph node—testicular cancer	0.000346	0.00278	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Epirubicin—testicular cancer	0.000346	0.0891	CbGdCrCtD
Bosutinib—MERTK—female gonad—testicular cancer	0.000343	0.00275	CbGeAlD
Bosutinib—PTK2—gonad—testicular cancer	0.000343	0.00275	CbGeAlD
Bosutinib—TBK1—gonad—testicular cancer	0.000343	0.00275	CbGeAlD
Bosutinib—BLK—lymph node—testicular cancer	0.000342	0.00275	CbGeAlD
Bosutinib—MAP4K1—testis—testicular cancer	0.000339	0.00272	CbGeAlD
Bosutinib—MAP3K19—testis—testicular cancer	0.000339	0.00272	CbGeAlD
Bosutinib—PHKG1—lymph node—testicular cancer	0.000339	0.00272	CbGeAlD
Bosutinib—CASK—lymph node—testicular cancer	0.000339	0.00272	CbGeAlD
Bosutinib—BTK—testis—testicular cancer	0.000338	0.00271	CbGeAlD
Bosutinib—MAP2K5—seminal vesicle—testicular cancer	0.000338	0.00271	CbGeAlD
Bosutinib—MAP4K4—female gonad—testicular cancer	0.000337	0.0027	CbGeAlD
Bosutinib—EIF2AK1—lymph node—testicular cancer	0.000335	0.00269	CbGeAlD
Bosutinib—BCR—female gonad—testicular cancer	0.000334	0.00268	CbGeAlD
Bosutinib—NUAK2—female gonad—testicular cancer	0.000334	0.00268	CbGeAlD
Bosutinib—TNK2—testis—testicular cancer	0.000333	0.00267	CbGeAlD
Bosutinib—MAP3K12—female gonad—testicular cancer	0.000332	0.00267	CbGeAlD
Bosutinib—CSF1R—seminal vesicle—testicular cancer	0.000329	0.00264	CbGeAlD
Bosutinib—MAP4K2—testis—testicular cancer	0.000328	0.00263	CbGeAlD
Bosutinib—TXK—lymph node—testicular cancer	0.000328	0.00263	CbGeAlD
Bosutinib—AXL—gonad—testicular cancer	0.000326	0.00262	CbGeAlD
Bosutinib—STK35—female gonad—testicular cancer	0.000325	0.00261	CbGeAlD
Bosutinib—MAP2K1—female gonad—testicular cancer	0.000325	0.00261	CbGeAlD
Bosutinib—FES—lymph node—testicular cancer	0.000325	0.00261	CbGeAlD
Bosutinib—VRK2—lymph node—testicular cancer	0.000325	0.00261	CbGeAlD
Bosutinib—ERBB4—testis—testicular cancer	0.000324	0.0026	CbGeAlD
Bosutinib—STK3—testis—testicular cancer	0.000324	0.0026	CbGeAlD
Bosutinib—CSK—female gonad—testicular cancer	0.000323	0.00259	CbGeAlD
Bosutinib—CSNK1A1—female gonad—testicular cancer	0.000321	0.00258	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—testicular cancer	0.00032	0.0824	CbGdCrCtD
Bosutinib—ROCK1—testis—testicular cancer	0.00032	0.00256	CbGeAlD
Bosutinib—HCK—female gonad—testicular cancer	0.000319	0.00256	CbGeAlD
Bosutinib—CLK1—female gonad—testicular cancer	0.000319	0.00256	CbGeAlD
Bosutinib—SYK—lymph node—testicular cancer	0.000318	0.00256	CbGeAlD
Bosutinib—TNIK—lymph node—testicular cancer	0.000318	0.00256	CbGeAlD
Bosutinib—ABL2—female gonad—testicular cancer	0.000317	0.00255	CbGeAlD
Bosutinib—CDK2—lymph node—testicular cancer	0.000315	0.00253	CbGeAlD
Bosutinib—CAMK2G—female gonad—testicular cancer	0.000313	0.00251	CbGeAlD
Bosutinib—BMP2K—female gonad—testicular cancer	0.000313	0.00251	CbGeAlD
Bosutinib—STK26—lymph node—testicular cancer	0.000312	0.00251	CbGeAlD
Bosutinib—PDGFRB—embryo—testicular cancer	0.000311	0.0025	CbGeAlD
Bosutinib—BMPR2—testis—testicular cancer	0.00031	0.00249	CbGeAlD
Bosutinib—LRRK2—female gonad—testicular cancer	0.00031	0.00249	CbGeAlD
Bosutinib—EGFR—female gonad—testicular cancer	0.000309	0.00248	CbGeAlD
Bosutinib—EPHB3—testis—testicular cancer	0.000308	0.00247	CbGeAlD
Bosutinib—STK36—testis—testicular cancer	0.000308	0.00247	CbGeAlD
Bosutinib—MERTK—testis—testicular cancer	0.000304	0.00244	CbGeAlD
Bosutinib—PTK2B—female gonad—testicular cancer	0.000302	0.00243	CbGeAlD
Bosutinib—CHEK2—lymph node—testicular cancer	0.000302	0.00242	CbGeAlD
Bosutinib—WEE1—lymph node—testicular cancer	0.000299	0.0024	CbGeAlD
Bosutinib—DMPK—lymph node—testicular cancer	0.000299	0.0024	CbGeAlD
Bosutinib—MAP4K4—testis—testicular cancer	0.000299	0.0024	CbGeAlD
Bosutinib—MAP4K5—gonad—testicular cancer	0.000299	0.0024	CbGeAlD
Bosutinib—MAP3K3—gonad—testicular cancer	0.000299	0.0024	CbGeAlD
Bosutinib—CSNK1E—female gonad—testicular cancer	0.000298	0.00239	CbGeAlD
Bosutinib—BCR—testis—testicular cancer	0.000297	0.00238	CbGeAlD
Bosutinib—NUAK2—testis—testicular cancer	0.000297	0.00238	CbGeAlD
Bosutinib—MAP3K12—testis—testicular cancer	0.000295	0.00236	CbGeAlD
Bosutinib—SIK1—female gonad—testicular cancer	0.000293	0.00235	CbGeAlD
Bosutinib—IRAK4—female gonad—testicular cancer	0.000293	0.00235	CbGeAlD
Bosutinib—PDGFRB—seminal vesicle—testicular cancer	0.000292	0.00235	CbGeAlD
Bosutinib—EPHA4—female gonad—testicular cancer	0.00029	0.00233	CbGeAlD
Bosutinib—MAP2K1—testis—testicular cancer	0.000289	0.00232	CbGeAlD
Bosutinib—STK35—testis—testicular cancer	0.000289	0.00232	CbGeAlD
Bosutinib—ERBB3—female gonad—testicular cancer	0.000287	0.0023	CbGeAlD
Bosutinib—CSK—testis—testicular cancer	0.000287	0.0023	CbGeAlD
Bosutinib—MAP2K2—female gonad—testicular cancer	0.000286	0.0023	CbGeAlD
Bosutinib—ULK3—female gonad—testicular cancer	0.000286	0.0023	CbGeAlD
Bosutinib—STK25—lymph node—testicular cancer	0.000286	0.00229	CbGeAlD
Bosutinib—CSNK1A1—testis—testicular cancer	0.000285	0.00229	CbGeAlD
Bosutinib—MAP3K2—female gonad—testicular cancer	0.000284	0.00228	CbGeAlD
Bosutinib—EPHA3—lymph node—testicular cancer	0.000284	0.00228	CbGeAlD
Bosutinib—HCK—testis—testicular cancer	0.000283	0.00227	CbGeAlD
Bosutinib—CLK1—testis—testicular cancer	0.000283	0.00227	CbGeAlD
Bosutinib—MAP3K7—female gonad—testicular cancer	0.000282	0.00226	CbGeAlD
Bosutinib—ABL2—testis—testicular cancer	0.000281	0.00226	CbGeAlD
Bosutinib—PTK2—female gonad—testicular cancer	0.000279	0.00224	CbGeAlD
Bosutinib—TBK1—female gonad—testicular cancer	0.000279	0.00224	CbGeAlD
Bosutinib—PLK2—lymph node—testicular cancer	0.000278	0.00223	CbGeAlD
Bosutinib—CAMK2G—testis—testicular cancer	0.000278	0.00223	CbGeAlD
Bosutinib—BMP2K—testis—testicular cancer	0.000278	0.00223	CbGeAlD
Bosutinib—ABL1—embryo—testicular cancer	0.000277	0.00223	CbGeAlD
Bosutinib—SIK3—lymph node—testicular cancer	0.000276	0.00222	CbGeAlD
Bosutinib—YES1—gonad—testicular cancer	0.000276	0.00221	CbGeAlD
Bosutinib—LRRK2—testis—testicular cancer	0.000275	0.00221	CbGeAlD
Bosutinib—EGFR—testis—testicular cancer	0.000274	0.0022	CbGeAlD
Bosutinib—STK10—gonad—testicular cancer	0.000273	0.00219	CbGeAlD
Bosutinib—IRAK1—female gonad—testicular cancer	0.000273	0.00219	CbGeAlD
Bosutinib—PTK2B—testis—testicular cancer	0.000268	0.00215	CbGeAlD
Bosutinib—RPS6KB1—female gonad—testicular cancer	0.000268	0.00215	CbGeAlD
Bosutinib—FGR—female gonad—testicular cancer	0.000266	0.00214	CbGeAlD
Bosutinib—LCK—female gonad—testicular cancer	0.000266	0.00214	CbGeAlD
Bosutinib—STK4—lymph node—testicular cancer	0.000266	0.00213	CbGeAlD
Bosutinib—AXL—female gonad—testicular cancer	0.000265	0.00213	CbGeAlD
Bosutinib—SRC—gonad—testicular cancer	0.000265	0.00213	CbGeAlD
Bosutinib—CSNK1E—testis—testicular cancer	0.000264	0.00212	CbGeAlD
Bosutinib—CHEK2—Vindesine—Vinblastine—testicular cancer	0.000263	0.0677	CbGdCrCtD
Bosutinib—CAMK1D—lymph node—testicular cancer	0.000263	0.00211	CbGeAlD
Bosutinib—ABL1—seminal vesicle—testicular cancer	0.00026	0.00209	CbGeAlD
Bosutinib—SIK1—testis—testicular cancer	0.00026	0.00209	CbGeAlD
Bosutinib—IRAK4—testis—testicular cancer	0.00026	0.00209	CbGeAlD
Bosutinib—STK24—lymph node—testicular cancer	0.000259	0.00208	CbGeAlD
Bosutinib—EPHA4—testis—testicular cancer	0.000257	0.00206	CbGeAlD
Bosutinib—SLK—female gonad—testicular cancer	0.000255	0.00205	CbGeAlD
Bosutinib—ERBB3—testis—testicular cancer	0.000255	0.00204	CbGeAlD
Bosutinib—MAP2K2—testis—testicular cancer	0.000254	0.00204	CbGeAlD
Bosutinib—ULK3—testis—testicular cancer	0.000254	0.00204	CbGeAlD
Bosutinib—EPHB4—female gonad—testicular cancer	0.000253	0.00203	CbGeAlD
Bosutinib—MAP3K2—testis—testicular cancer	0.000252	0.00202	CbGeAlD
Bosutinib—FER—lymph node—testicular cancer	0.000251	0.00202	CbGeAlD
Bosutinib—ALK—lymph node—testicular cancer	0.000251	0.00202	CbGeAlD
Bosutinib—MAP3K7—testis—testicular cancer	0.00025	0.00201	CbGeAlD
Bosutinib—EPHA2—female gonad—testicular cancer	0.000249	0.002	CbGeAlD
Bosutinib—FYN—female gonad—testicular cancer	0.000248	0.00199	CbGeAlD
Bosutinib—PTK2—testis—testicular cancer	0.000247	0.00198	CbGeAlD
Bosutinib—TBK1—testis—testicular cancer	0.000247	0.00198	CbGeAlD
Bosutinib—MAP4K1—lymph node—testicular cancer	0.000246	0.00197	CbGeAlD
Bosutinib—ERBB3—Podofilox—Etoposide—testicular cancer	0.000246	0.0632	CbGdCrCtD
Bosutinib—BTK—lymph node—testicular cancer	0.000245	0.00196	CbGeAlD
Bosutinib—MAP3K3—female gonad—testicular cancer	0.000243	0.00195	CbGeAlD
Bosutinib—MAP4K5—female gonad—testicular cancer	0.000243	0.00195	CbGeAlD
Bosutinib—IRAK1—testis—testicular cancer	0.000242	0.00194	CbGeAlD
Bosutinib—TNK2—lymph node—testicular cancer	0.000241	0.00194	CbGeAlD
Bosutinib—CSF1R—gonad—testicular cancer	0.000238	0.00191	CbGeAlD
Bosutinib—MAP4K2—lymph node—testicular cancer	0.000238	0.00191	CbGeAlD
Bosutinib—RPS6KB1—testis—testicular cancer	0.000238	0.00191	CbGeAlD
Bosutinib—LCK—testis—testicular cancer	0.000236	0.0019	CbGeAlD
Bosutinib—FGR—testis—testicular cancer	0.000236	0.0019	CbGeAlD
Bosutinib—AXL—testis—testicular cancer	0.000235	0.00189	CbGeAlD
Bosutinib—STK3—lymph node—testicular cancer	0.000235	0.00188	CbGeAlD
Bosutinib—SLK—testis—testicular cancer	0.000226	0.00182	CbGeAlD
Bosutinib—BMPR2—lymph node—testicular cancer	0.000225	0.00181	CbGeAlD
Bosutinib—EPHB4—testis—testicular cancer	0.000225	0.0018	CbGeAlD
Bosutinib—YES1—female gonad—testicular cancer	0.000224	0.0018	CbGeAlD
Bosutinib—EPHB3—lymph node—testicular cancer	0.000223	0.00179	CbGeAlD
Bosutinib—STK36—lymph node—testicular cancer	0.000223	0.00179	CbGeAlD
Bosutinib—STK10—female gonad—testicular cancer	0.000222	0.00178	CbGeAlD
Bosutinib—TAOK3—female gonad—testicular cancer	0.000221	0.00178	CbGeAlD
Bosutinib—MERTK—lymph node—testicular cancer	0.000221	0.00177	CbGeAlD
Bosutinib—EPHA2—testis—testicular cancer	0.000221	0.00177	CbGeAlD
Bosutinib—FYN—testis—testicular cancer	0.00022	0.00177	CbGeAlD
Bosutinib—MAP4K4—lymph node—testicular cancer	0.000217	0.00174	CbGeAlD
Bosutinib—SRC—female gonad—testicular cancer	0.000216	0.00173	CbGeAlD
Bosutinib—MAP4K5—testis—testicular cancer	0.000215	0.00173	CbGeAlD
Bosutinib—MAP3K3—testis—testicular cancer	0.000215	0.00173	CbGeAlD
Bosutinib—NUAK2—lymph node—testicular cancer	0.000215	0.00173	CbGeAlD
Bosutinib—BCR—lymph node—testicular cancer	0.000215	0.00173	CbGeAlD
Bosutinib—MAP3K12—lymph node—testicular cancer	0.000214	0.00171	CbGeAlD
Bosutinib—PDGFRB—gonad—testicular cancer	0.000211	0.0017	CbGeAlD
Bosutinib—MAP2K1—lymph node—testicular cancer	0.000209	0.00168	CbGeAlD
Bosutinib—STK35—lymph node—testicular cancer	0.000209	0.00168	CbGeAlD
Bosutinib—CSK—lymph node—testicular cancer	0.000208	0.00167	CbGeAlD
Bosutinib—CSNK1A1—lymph node—testicular cancer	0.000206	0.00166	CbGeAlD
Bosutinib—HCK—lymph node—testicular cancer	0.000205	0.00165	CbGeAlD
Bosutinib—CLK1—lymph node—testicular cancer	0.000205	0.00165	CbGeAlD
Bosutinib—ABL2—lymph node—testicular cancer	0.000204	0.00164	CbGeAlD
Bosutinib—CAMK2G—lymph node—testicular cancer	0.000201	0.00162	CbGeAlD
Bosutinib—BMP2K—lymph node—testicular cancer	0.000201	0.00162	CbGeAlD
Bosutinib—LRRK2—lymph node—testicular cancer	0.0002	0.0016	CbGeAlD
Bosutinib—EGFR—lymph node—testicular cancer	0.000199	0.0016	CbGeAlD
Bosutinib—YES1—testis—testicular cancer	0.000199	0.00159	CbGeAlD
Bosutinib—MAP2K5—female gonad—testicular cancer	0.000198	0.00159	CbGeAlD
Bosutinib—STK10—testis—testicular cancer	0.000197	0.00158	CbGeAlD
Bosutinib—TAOK3—testis—testicular cancer	0.000196	0.00157	CbGeAlD
Bosutinib—PTK2B—lymph node—testicular cancer	0.000194	0.00156	CbGeAlD
Bosutinib—CSF1R—female gonad—testicular cancer	0.000193	0.00155	CbGeAlD
Bosutinib—CSNK1E—lymph node—testicular cancer	0.000191	0.00154	CbGeAlD
Bosutinib—SRC—testis—testicular cancer	0.000191	0.00153	CbGeAlD
Bosutinib—SIK1—lymph node—testicular cancer	0.000188	0.00151	CbGeAlD
Bosutinib—IRAK4—lymph node—testicular cancer	0.000188	0.00151	CbGeAlD
Bosutinib—ABL1—gonad—testicular cancer	0.000188	0.00151	CbGeAlD
Bosutinib—EPHA4—lymph node—testicular cancer	0.000186	0.0015	CbGeAlD
Bosutinib—ERBB3—lymph node—testicular cancer	0.000185	0.00148	CbGeAlD
Bosutinib—MAP2K2—lymph node—testicular cancer	0.000184	0.00148	CbGeAlD
Bosutinib—ULK3—lymph node—testicular cancer	0.000184	0.00148	CbGeAlD
Bosutinib—MAP3K2—lymph node—testicular cancer	0.000183	0.00147	CbGeAlD
Bosutinib—MAP3K7—lymph node—testicular cancer	0.000181	0.00145	CbGeAlD
Bosutinib—PTK2—lymph node—testicular cancer	0.000179	0.00144	CbGeAlD
Bosutinib—TBK1—lymph node—testicular cancer	0.000179	0.00144	CbGeAlD
Bosutinib—MAP2K5—testis—testicular cancer	0.000176	0.00141	CbGeAlD
Bosutinib—IRAK1—lymph node—testicular cancer	0.000176	0.00141	CbGeAlD
Bosutinib—RPS6KB1—lymph node—testicular cancer	0.000172	0.00138	CbGeAlD
Bosutinib—CSF1R—testis—testicular cancer	0.000172	0.00138	CbGeAlD
Bosutinib—PDGFRB—female gonad—testicular cancer	0.000172	0.00138	CbGeAlD
Bosutinib—LCK—lymph node—testicular cancer	0.000171	0.00137	CbGeAlD
Bosutinib—FGR—lymph node—testicular cancer	0.000171	0.00137	CbGeAlD
Bosutinib—AXL—lymph node—testicular cancer	0.000171	0.00137	CbGeAlD
Bosutinib—CHEK2—Vinorelbine—Vinblastine—testicular cancer	0.000166	0.0427	CbGdCrCtD
Bosutinib—CHEK2—Podofilox—Etoposide—testicular cancer	0.000166	0.0427	CbGdCrCtD
Bosutinib—CHEK2—Teniposide—Etoposide—testicular cancer	0.000166	0.0427	CbGdCrCtD
Bosutinib—SLK—lymph node—testicular cancer	0.000164	0.00132	CbGeAlD
Bosutinib—EPHB4—lymph node—testicular cancer	0.000163	0.00131	CbGeAlD
Bosutinib—EPHA2—lymph node—testicular cancer	0.00016	0.00128	CbGeAlD
Bosutinib—FYN—lymph node—testicular cancer	0.00016	0.00128	CbGeAlD
Bosutinib—MAP4K5—lymph node—testicular cancer	0.000156	0.00125	CbGeAlD
Bosutinib—MAP3K3—lymph node—testicular cancer	0.000156	0.00125	CbGeAlD
Bosutinib—ABL1—female gonad—testicular cancer	0.000153	0.00123	CbGeAlD
Bosutinib—PDGFRB—testis—testicular cancer	0.000152	0.00122	CbGeAlD
Bosutinib—YES1—lymph node—testicular cancer	0.000144	0.00116	CbGeAlD
Bosutinib—STK10—lymph node—testicular cancer	0.000143	0.00115	CbGeAlD
Bosutinib—TAOK3—lymph node—testicular cancer	0.000142	0.00114	CbGeAlD
Bosutinib—CHEK2—Vincristine—Vinblastine—testicular cancer	0.000142	0.0365	CbGdCrCtD
Bosutinib—SRC—lymph node—testicular cancer	0.000139	0.00111	CbGeAlD
Bosutinib—ABL1—testis—testicular cancer	0.000136	0.00109	CbGeAlD
Bosutinib—Chest pain—Etoposide—testicular cancer	0.00013	0.00113	CcSEcCtD
Bosutinib—Nausea—Vinblastine—testicular cancer	0.00013	0.00113	CcSEcCtD
Bosutinib—Abdominal pain upper—Epirubicin—testicular cancer	0.00013	0.00113	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000129	0.00113	CcSEcCtD
Bosutinib—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000129	0.00112	CcSEcCtD
Bosutinib—Discomfort—Etoposide—testicular cancer	0.000128	0.00112	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000128	0.00112	CcSEcCtD
Bosutinib—MAP2K5—lymph node—testicular cancer	0.000127	0.00102	CbGeAlD
Bosutinib—Nasopharyngitis—Epirubicin—testicular cancer	0.000127	0.00111	CcSEcCtD
Bosutinib—Face oedema—Doxorubicin—testicular cancer	0.000127	0.00111	CcSEcCtD
Bosutinib—Abdominal discomfort—Methotrexate—testicular cancer	0.000126	0.0011	CcSEcCtD
Bosutinib—Gastritis—Epirubicin—testicular cancer	0.000126	0.0011	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000125	0.00109	CcSEcCtD
Bosutinib—Urticaria—Ifosfamide—testicular cancer	0.000125	0.00109	CcSEcCtD
Bosutinib—Body temperature increased—Ifosfamide—testicular cancer	0.000125	0.00109	CcSEcCtD
Bosutinib—Abdominal pain—Ifosfamide—testicular cancer	0.000125	0.00109	CcSEcCtD
Bosutinib—Pancytopenia—Methotrexate—testicular cancer	0.000125	0.00109	CcSEcCtD
Bosutinib—Anaphylactic shock—Etoposide—testicular cancer	0.000125	0.00109	CcSEcCtD
Bosutinib—CSF1R—lymph node—testicular cancer	0.000124	0.000998	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000124	0.00108	CcSEcCtD
Bosutinib—Infection—Etoposide—testicular cancer	0.000124	0.00108	CcSEcCtD
Bosutinib—Asthenia—Dactinomycin—testicular cancer	0.000123	0.00108	CcSEcCtD
Bosutinib—Blood creatinine increased—Doxorubicin—testicular cancer	0.000123	0.00107	CcSEcCtD
Bosutinib—Influenza—Epirubicin—testicular cancer	0.000123	0.00107	CcSEcCtD
Bosutinib—Neutropenia—Methotrexate—testicular cancer	0.000123	0.00107	CcSEcCtD
Bosutinib—Dehydration—Doxorubicin—testicular cancer	0.000122	0.00107	CcSEcCtD
Bosutinib—Thrombocytopenia—Etoposide—testicular cancer	0.000122	0.00106	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000122	0.00106	CcSEcCtD
Bosutinib—Dyspnoea—Cisplatin—testicular cancer	0.000121	0.00106	CcSEcCtD
Bosutinib—Skin disorder—Etoposide—testicular cancer	0.000121	0.00106	CcSEcCtD
Bosutinib—Abdominal pain upper—Doxorubicin—testicular cancer	0.00012	0.00105	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000118	0.00103	CcSEcCtD
Bosutinib—CSK—Daunorubicin—Epirubicin—testicular cancer	0.000118	0.0304	CbGdCrCtD
Bosutinib—CSK—Doxorubicin—Epirubicin—testicular cancer	0.000118	0.0304	CbGdCrCtD
Bosutinib—Decreased appetite—Cisplatin—testicular cancer	0.000118	0.00103	CcSEcCtD
Bosutinib—Bronchitis—Epirubicin—testicular cancer	0.000118	0.00103	CcSEcCtD
Bosutinib—Diarrhoea—Dactinomycin—testicular cancer	0.000118	0.00103	CcSEcCtD
Bosutinib—Pneumonia—Methotrexate—testicular cancer	0.000118	0.00103	CcSEcCtD
Bosutinib—Nasopharyngitis—Doxorubicin—testicular cancer	0.000118	0.00103	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000117	0.00102	CcSEcCtD
Bosutinib—Vomiting—Bleomycin—testicular cancer	0.000117	0.00102	CcSEcCtD
Bosutinib—Infestation NOS—Methotrexate—testicular cancer	0.000117	0.00102	CcSEcCtD
Bosutinib—Infestation—Methotrexate—testicular cancer	0.000117	0.00102	CcSEcCtD
Bosutinib—Pancytopenia—Epirubicin—testicular cancer	0.000117	0.00102	CcSEcCtD
Bosutinib—Rash—Bleomycin—testicular cancer	0.000116	0.00101	CcSEcCtD
Bosutinib—Gastritis—Doxorubicin—testicular cancer	0.000116	0.00101	CcSEcCtD
Bosutinib—Pain—Cisplatin—testicular cancer	0.000116	0.00101	CcSEcCtD
Bosutinib—Dermatitis—Bleomycin—testicular cancer	0.000116	0.00101	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000116	0.00101	CcSEcCtD
Bosutinib—Renal failure—Methotrexate—testicular cancer	0.000115	0.001	CcSEcCtD
Bosutinib—Neutropenia—Epirubicin—testicular cancer	0.000115	0.001	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000114	0.000995	CcSEcCtD
Bosutinib—Influenza—Doxorubicin—testicular cancer	0.000114	0.000991	CcSEcCtD
Bosutinib—Asthenia—Ifosfamide—testicular cancer	0.000113	0.000987	CcSEcCtD
Bosutinib—Feeling abnormal—Cisplatin—testicular cancer	0.000112	0.000977	CcSEcCtD
Bosutinib—Pruritus—Ifosfamide—testicular cancer	0.000112	0.000973	CcSEcCtD
Bosutinib—Dyspnoea—Etoposide—testicular cancer	0.000111	0.000969	CcSEcCtD
Bosutinib—Hepatobiliary disease—Methotrexate—testicular cancer	0.000111	0.000965	CcSEcCtD
Bosutinib—PDGFRB—lymph node—testicular cancer	0.00011	0.000886	CbGeAlD
Bosutinib—Pneumonia—Epirubicin—testicular cancer	0.00011	0.00096	CcSEcCtD
Bosutinib—Nausea—Bleomycin—testicular cancer	0.00011	0.000956	CcSEcCtD
Bosutinib—Infestation—Epirubicin—testicular cancer	0.000109	0.000955	CcSEcCtD
Bosutinib—Infestation NOS—Epirubicin—testicular cancer	0.000109	0.000955	CcSEcCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—testicular cancer	0.000109	0.0281	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—testicular cancer	0.000109	0.0281	CbGdCrCtD
Bosutinib—Vomiting—Dactinomycin—testicular cancer	0.000109	0.000954	CcSEcCtD
Bosutinib—Bronchitis—Doxorubicin—testicular cancer	0.000109	0.000953	CcSEcCtD
Bosutinib—Agranulocytosis—Methotrexate—testicular cancer	0.000109	0.000952	CcSEcCtD
Bosutinib—Rash—Dactinomycin—testicular cancer	0.000108	0.000946	CcSEcCtD
Bosutinib—Decreased appetite—Etoposide—testicular cancer	0.000108	0.000944	CcSEcCtD
Bosutinib—Diarrhoea—Ifosfamide—testicular cancer	0.000108	0.000941	CcSEcCtD
Bosutinib—Pancytopenia—Doxorubicin—testicular cancer	0.000108	0.000941	CcSEcCtD
Bosutinib—Renal failure—Epirubicin—testicular cancer	0.000108	0.000939	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Etoposide—testicular cancer	0.000108	0.000938	CcSEcCtD
Bosutinib—Body temperature increased—Cisplatin—testicular cancer	0.000107	0.000937	CcSEcCtD
Bosutinib—Fatigue—Etoposide—testicular cancer	0.000107	0.000937	CcSEcCtD
Bosutinib—Pain—Etoposide—testicular cancer	0.000106	0.000929	CcSEcCtD
Bosutinib—Neutropenia—Doxorubicin—testicular cancer	0.000106	0.000927	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000106	0.000921	CcSEcCtD
Bosutinib—Hepatitis—Methotrexate—testicular cancer	0.000105	0.000916	CcSEcCtD
Bosutinib—Dizziness—Ifosfamide—testicular cancer	0.000104	0.00091	CcSEcCtD
Bosutinib—Urinary tract disorder—Methotrexate—testicular cancer	0.000104	0.000904	CcSEcCtD
Bosutinib—Hepatobiliary disease—Epirubicin—testicular cancer	0.000104	0.000903	CcSEcCtD
Bosutinib—Urethral disorder—Methotrexate—testicular cancer	0.000103	0.000898	CcSEcCtD
Bosutinib—Feeling abnormal—Etoposide—testicular cancer	0.000103	0.000895	CcSEcCtD
Bosutinib—Nausea—Dactinomycin—testicular cancer	0.000102	0.000892	CcSEcCtD
Bosutinib—Agranulocytosis—Epirubicin—testicular cancer	0.000102	0.000891	CcSEcCtD
Bosutinib—Pneumonia—Doxorubicin—testicular cancer	0.000102	0.000889	CcSEcCtD
Bosutinib—Gastrointestinal pain—Etoposide—testicular cancer	0.000102	0.000888	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—testicular cancer	0.000101	0.000883	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—testicular cancer	0.000101	0.000883	CcSEcCtD
Bosutinib—Vomiting—Ifosfamide—testicular cancer	0.0001	0.000875	CcSEcCtD
Bosutinib—Renal failure—Doxorubicin—testicular cancer	9.95e-05	0.000868	CcSEcCtD
Bosutinib—Rash—Ifosfamide—testicular cancer	9.94e-05	0.000867	CcSEcCtD
Bosutinib—Dermatitis—Ifosfamide—testicular cancer	9.93e-05	0.000866	CcSEcCtD
Bosutinib—Erythema multiforme—Methotrexate—testicular cancer	9.93e-05	0.000866	CcSEcCtD
Bosutinib—Urticaria—Etoposide—testicular cancer	9.89e-05	0.000863	CcSEcCtD
Bosutinib—Body temperature increased—Etoposide—testicular cancer	9.84e-05	0.000859	CcSEcCtD
Bosutinib—Abdominal pain—Etoposide—testicular cancer	9.84e-05	0.000859	CcSEcCtD
Bosutinib—ABL1—lymph node—testicular cancer	9.83e-05	0.000789	CbGeAlD
Bosutinib—Hepatitis—Epirubicin—testicular cancer	9.82e-05	0.000857	CcSEcCtD
Bosutinib—Tinnitus—Methotrexate—testicular cancer	9.79e-05	0.000854	CcSEcCtD
Bosutinib—Asthenia—Cisplatin—testicular cancer	9.75e-05	0.000851	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—testicular cancer	9.74e-05	0.00085	CcSEcCtD
Bosutinib—Urinary tract disorder—Epirubicin—testicular cancer	9.7e-05	0.000846	CcSEcCtD
Bosutinib—Oedema peripheral—Epirubicin—testicular cancer	9.68e-05	0.000844	CcSEcCtD
Bosutinib—Connective tissue disorder—Epirubicin—testicular cancer	9.65e-05	0.000842	CcSEcCtD
Bosutinib—Urethral disorder—Epirubicin—testicular cancer	9.63e-05	0.00084	CcSEcCtD
Bosutinib—Hepatobiliary disease—Doxorubicin—testicular cancer	9.58e-05	0.000836	CcSEcCtD
Bosutinib—Immune system disorder—Methotrexate—testicular cancer	9.48e-05	0.000827	CcSEcCtD
Bosutinib—Mediastinal disorder—Methotrexate—testicular cancer	9.46e-05	0.000825	CcSEcCtD
Bosutinib—Agranulocytosis—Doxorubicin—testicular cancer	9.45e-05	0.000824	CcSEcCtD
Bosutinib—Nausea—Ifosfamide—testicular cancer	9.36e-05	0.000817	CcSEcCtD
Bosutinib—Diarrhoea—Cisplatin—testicular cancer	9.3e-05	0.000811	CcSEcCtD
Bosutinib—Erythema multiforme—Epirubicin—testicular cancer	9.29e-05	0.00081	CcSEcCtD
Bosutinib—Tinnitus—Epirubicin—testicular cancer	9.16e-05	0.000799	CcSEcCtD
Bosutinib—Malnutrition—Methotrexate—testicular cancer	9.14e-05	0.000797	CcSEcCtD
Bosutinib—Cardiac disorder—Epirubicin—testicular cancer	9.12e-05	0.000795	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—testicular cancer	9.09e-05	0.000793	CcSEcCtD
Bosutinib—Urinary tract disorder—Doxorubicin—testicular cancer	8.98e-05	0.000783	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—testicular cancer	8.96e-05	0.000781	CcSEcCtD
Bosutinib—Dysgeusia—Methotrexate—testicular cancer	8.95e-05	0.000781	CcSEcCtD
Bosutinib—Asthenia—Etoposide—testicular cancer	8.93e-05	0.000779	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—testicular cancer	8.93e-05	0.000779	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—testicular cancer	8.91e-05	0.000777	CcSEcCtD
Bosutinib—Immune system disorder—Epirubicin—testicular cancer	8.87e-05	0.000774	CcSEcCtD
Bosutinib—Mediastinal disorder—Epirubicin—testicular cancer	8.85e-05	0.000772	CcSEcCtD
Bosutinib—Back pain—Methotrexate—testicular cancer	8.84e-05	0.000771	CcSEcCtD
Bosutinib—Pruritus—Etoposide—testicular cancer	8.81e-05	0.000769	CcSEcCtD
Bosutinib—CHEK2—Doxorubicin—Epirubicin—testicular cancer	8.65e-05	0.0223	CbGdCrCtD
Bosutinib—Vomiting—Cisplatin—testicular cancer	8.64e-05	0.000754	CcSEcCtD
Bosutinib—ABCB1—embryo—testicular cancer	8.62e-05	0.000692	CbGeAlD
Bosutinib—Erythema multiforme—Doxorubicin—testicular cancer	8.6e-05	0.00075	CcSEcCtD
Bosutinib—Rash—Cisplatin—testicular cancer	8.57e-05	0.000748	CcSEcCtD
Bosutinib—Dermatitis—Cisplatin—testicular cancer	8.56e-05	0.000747	CcSEcCtD
Bosutinib—Malnutrition—Epirubicin—testicular cancer	8.55e-05	0.000746	CcSEcCtD
Bosutinib—Diarrhoea—Etoposide—testicular cancer	8.52e-05	0.000743	CcSEcCtD
Bosutinib—Ill-defined disorder—Methotrexate—testicular cancer	8.48e-05	0.00074	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—testicular cancer	8.48e-05	0.000739	CcSEcCtD
Bosutinib—Anaemia—Methotrexate—testicular cancer	8.45e-05	0.000737	CcSEcCtD
Bosutinib—Cardiac disorder—Doxorubicin—testicular cancer	8.44e-05	0.000736	CcSEcCtD
Bosutinib—Dysgeusia—Epirubicin—testicular cancer	8.38e-05	0.000731	CcSEcCtD
Bosutinib—Back pain—Epirubicin—testicular cancer	8.27e-05	0.000722	CcSEcCtD
Bosutinib—ABL1—Doxorubicin—Epirubicin—testicular cancer	8.26e-05	0.0212	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Epirubicin—testicular cancer	8.26e-05	0.0212	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Epirubicin—testicular cancer	8.26e-05	0.0212	CbGdCrCtD
Bosutinib—Malaise—Methotrexate—testicular cancer	8.24e-05	0.000719	CcSEcCtD
Bosutinib—Dizziness—Etoposide—testicular cancer	8.23e-05	0.000718	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—testicular cancer	8.21e-05	0.000716	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—testicular cancer	8.19e-05	0.000715	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—testicular cancer	8.18e-05	0.000714	CcSEcCtD
Bosutinib—ABCB1—seminal vesicle—testicular cancer	8.1e-05	0.00065	CbGeAlD
Bosutinib—Nausea—Cisplatin—testicular cancer	8.07e-05	0.000704	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—testicular cancer	8.01e-05	0.0206	CbGdCrCtD
Bosutinib—Cough—Methotrexate—testicular cancer	7.97e-05	0.000696	CcSEcCtD
Bosutinib—Ill-defined disorder—Epirubicin—testicular cancer	7.94e-05	0.000692	CcSEcCtD
Bosutinib—Vomiting—Etoposide—testicular cancer	7.92e-05	0.000691	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—testicular cancer	7.91e-05	0.00069	CcSEcCtD
Bosutinib—Anaemia—Epirubicin—testicular cancer	7.9e-05	0.00069	CcSEcCtD
Bosutinib—Rash—Etoposide—testicular cancer	7.85e-05	0.000685	CcSEcCtD
Bosutinib—Dermatitis—Etoposide—testicular cancer	7.84e-05	0.000684	CcSEcCtD
Bosutinib—Headache—Etoposide—testicular cancer	7.8e-05	0.000681	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—testicular cancer	7.78e-05	0.000679	CcSEcCtD
Bosutinib—Arthralgia—Methotrexate—testicular cancer	7.78e-05	0.000679	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—testicular cancer	7.78e-05	0.000679	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—testicular cancer	7.75e-05	0.000676	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	7.73e-05	0.000674	CcSEcCtD
Bosutinib—Malaise—Epirubicin—testicular cancer	7.71e-05	0.000673	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—testicular cancer	7.69e-05	0.000671	CcSEcCtD
Bosutinib—Leukopenia—Epirubicin—testicular cancer	7.66e-05	0.000668	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—testicular cancer	7.65e-05	0.000668	CcSEcCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—testicular cancer	7.64e-05	0.0197	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—testicular cancer	7.64e-05	0.0197	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—testicular cancer	7.64e-05	0.0197	CbGdCrCtD
Bosutinib—Cough—Epirubicin—testicular cancer	7.46e-05	0.000651	CcSEcCtD
Bosutinib—Anaphylactic shock—Methotrexate—testicular cancer	7.46e-05	0.000651	CcSEcCtD
Bosutinib—Infection—Methotrexate—testicular cancer	7.41e-05	0.000646	CcSEcCtD
Bosutinib—Nausea—Etoposide—testicular cancer	7.4e-05	0.000645	CcSEcCtD
Bosutinib—Ill-defined disorder—Doxorubicin—testicular cancer	7.34e-05	0.000641	CcSEcCtD
Bosutinib—Nervous system disorder—Methotrexate—testicular cancer	7.31e-05	0.000638	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—testicular cancer	7.31e-05	0.000638	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—testicular cancer	7.3e-05	0.000637	CcSEcCtD
Bosutinib—Arthralgia—Epirubicin—testicular cancer	7.28e-05	0.000635	CcSEcCtD
Bosutinib—Myalgia—Epirubicin—testicular cancer	7.28e-05	0.000635	CcSEcCtD
Bosutinib—Chest pain—Epirubicin—testicular cancer	7.28e-05	0.000635	CcSEcCtD
Bosutinib—Skin disorder—Methotrexate—testicular cancer	7.24e-05	0.000632	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	7.23e-05	0.000631	CcSEcCtD
Bosutinib—Discomfort—Epirubicin—testicular cancer	7.19e-05	0.000628	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—testicular cancer	7.14e-05	0.000623	CcSEcCtD
Bosutinib—Leukopenia—Doxorubicin—testicular cancer	7.08e-05	0.000618	CcSEcCtD
Bosutinib—Anaphylactic shock—Epirubicin—testicular cancer	6.98e-05	0.000609	CcSEcCtD
Bosutinib—Oedema—Epirubicin—testicular cancer	6.98e-05	0.000609	CcSEcCtD
Bosutinib—Infection—Epirubicin—testicular cancer	6.93e-05	0.000605	CcSEcCtD
Bosutinib—Cough—Doxorubicin—testicular cancer	6.91e-05	0.000602	CcSEcCtD
Bosutinib—Nervous system disorder—Epirubicin—testicular cancer	6.85e-05	0.000597	CcSEcCtD
Bosutinib—Thrombocytopenia—Epirubicin—testicular cancer	6.83e-05	0.000596	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methotrexate—testicular cancer	6.8e-05	0.000593	CcSEcCtD
Bosutinib—Skin disorder—Epirubicin—testicular cancer	6.78e-05	0.000591	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—testicular cancer	6.74e-05	0.000588	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—testicular cancer	6.74e-05	0.000588	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—testicular cancer	6.74e-05	0.000588	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	6.69e-05	0.000584	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—testicular cancer	6.66e-05	0.000581	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—testicular cancer	6.65e-05	0.00058	CcSEcCtD
Bosutinib—Decreased appetite—Methotrexate—testicular cancer	6.48e-05	0.000566	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—testicular cancer	6.46e-05	0.000563	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—testicular cancer	6.46e-05	0.000563	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—testicular cancer	6.44e-05	0.000562	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—testicular cancer	6.43e-05	0.000561	CcSEcCtD
Bosutinib—Infection—Doxorubicin—testicular cancer	6.42e-05	0.00056	CcSEcCtD
Bosutinib—Pain—Methotrexate—testicular cancer	6.38e-05	0.000556	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Epirubicin—testicular cancer	6.36e-05	0.000555	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—testicular cancer	6.33e-05	0.000553	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—testicular cancer	6.32e-05	0.000552	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—testicular cancer	6.27e-05	0.000547	CcSEcCtD
Bosutinib—Dyspnoea—Epirubicin—testicular cancer	6.22e-05	0.000543	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—testicular cancer	6.15e-05	0.000536	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—testicular cancer	6.1e-05	0.000532	CcSEcCtD
Bosutinib—Decreased appetite—Epirubicin—testicular cancer	6.07e-05	0.000529	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Epirubicin—testicular cancer	6.03e-05	0.000526	CcSEcCtD
Bosutinib—Fatigue—Epirubicin—testicular cancer	6.02e-05	0.000525	CcSEcCtD
Bosutinib—Pain—Epirubicin—testicular cancer	5.97e-05	0.000521	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—testicular cancer	5.93e-05	0.000517	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—testicular cancer	5.9e-05	0.000514	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—testicular cancer	5.9e-05	0.000514	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	5.88e-05	0.000513	CcSEcCtD
Bosutinib—ABCB1—gonad—testicular cancer	5.85e-05	0.00047	CbGeAlD
Bosutinib—Dyspnoea—Doxorubicin—testicular cancer	5.76e-05	0.000502	CcSEcCtD
Bosutinib—Feeling abnormal—Epirubicin—testicular cancer	5.75e-05	0.000502	CcSEcCtD
Bosutinib—Gastrointestinal pain—Epirubicin—testicular cancer	5.71e-05	0.000498	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—testicular cancer	5.61e-05	0.00049	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—testicular cancer	5.58e-05	0.000486	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—testicular cancer	5.57e-05	0.000486	CcSEcCtD
Bosutinib—Urticaria—Epirubicin—testicular cancer	5.54e-05	0.000484	CcSEcCtD
Bosutinib—Pain—Doxorubicin—testicular cancer	5.52e-05	0.000482	CcSEcCtD
Bosutinib—Body temperature increased—Epirubicin—testicular cancer	5.52e-05	0.000481	CcSEcCtD
Bosutinib—Abdominal pain—Epirubicin—testicular cancer	5.52e-05	0.000481	CcSEcCtD
Bosutinib—Asthenia—Methotrexate—testicular cancer	5.35e-05	0.000467	CcSEcCtD
Bosutinib—Feeling abnormal—Doxorubicin—testicular cancer	5.32e-05	0.000464	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—testicular cancer	5.28e-05	0.000461	CcSEcCtD
Bosutinib—Pruritus—Methotrexate—testicular cancer	5.28e-05	0.00046	CcSEcCtD
Bosutinib—Urticaria—Doxorubicin—testicular cancer	5.13e-05	0.000448	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—testicular cancer	5.11e-05	0.000445	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—testicular cancer	5.11e-05	0.000445	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—testicular cancer	5.1e-05	0.000445	CcSEcCtD
Bosutinib—Asthenia—Epirubicin—testicular cancer	5.01e-05	0.000437	CcSEcCtD
Bosutinib—Pruritus—Epirubicin—testicular cancer	4.94e-05	0.000431	CcSEcCtD
Bosutinib—Dizziness—Methotrexate—testicular cancer	4.93e-05	0.00043	CcSEcCtD
Bosutinib—Diarrhoea—Epirubicin—testicular cancer	4.78e-05	0.000417	CcSEcCtD
Bosutinib—ABCB1—female gonad—testicular cancer	4.76e-05	0.000382	CbGeAlD
Bosutinib—Vomiting—Methotrexate—testicular cancer	4.74e-05	0.000414	CcSEcCtD
Bosutinib—Rash—Methotrexate—testicular cancer	4.7e-05	0.00041	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—testicular cancer	4.7e-05	0.00041	CcSEcCtD
Bosutinib—Headache—Methotrexate—testicular cancer	4.67e-05	0.000408	CcSEcCtD
Bosutinib—Asthenia—Doxorubicin—testicular cancer	4.63e-05	0.000404	CcSEcCtD
Bosutinib—Dizziness—Epirubicin—testicular cancer	4.62e-05	0.000403	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—testicular cancer	4.57e-05	0.000399	CcSEcCtD
Bosutinib—Vomiting—Epirubicin—testicular cancer	4.44e-05	0.000387	CcSEcCtD
Bosutinib—Nausea—Methotrexate—testicular cancer	4.43e-05	0.000387	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—testicular cancer	4.42e-05	0.000386	CcSEcCtD
Bosutinib—Rash—Epirubicin—testicular cancer	4.4e-05	0.000384	CcSEcCtD
Bosutinib—Dermatitis—Epirubicin—testicular cancer	4.4e-05	0.000384	CcSEcCtD
Bosutinib—Headache—Epirubicin—testicular cancer	4.37e-05	0.000381	CcSEcCtD
Bosutinib—Dizziness—Doxorubicin—testicular cancer	4.27e-05	0.000373	CcSEcCtD
Bosutinib—ABCB1—testis—testicular cancer	4.22e-05	0.000339	CbGeAlD
Bosutinib—Nausea—Epirubicin—testicular cancer	4.15e-05	0.000362	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—testicular cancer	4.11e-05	0.000358	CcSEcCtD
Bosutinib—Rash—Doxorubicin—testicular cancer	4.07e-05	0.000355	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—testicular cancer	4.07e-05	0.000355	CcSEcCtD
Bosutinib—Headache—Doxorubicin—testicular cancer	4.05e-05	0.000353	CcSEcCtD
Bosutinib—Nausea—Doxorubicin—testicular cancer	3.84e-05	0.000335	CcSEcCtD
Bosutinib—ABCB1—lymph node—testicular cancer	3.06e-05	0.000245	CbGeAlD
Bosutinib—FES—Signaling Pathways—FGFR3—testicular cancer	1.65e-05	0.000134	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—FGFR3—testicular cancer	1.64e-05	0.000134	CbGpPWpGaD
Bosutinib—ERBB3—Disease—KITLG—testicular cancer	1.63e-05	0.000133	CbGpPWpGaD
Bosutinib—EGFR—Immune System—BCL10—testicular cancer	1.63e-05	0.000133	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—H2AFZ—testicular cancer	1.63e-05	0.000133	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—KITLG—testicular cancer	1.62e-05	0.000132	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—KIT—testicular cancer	1.62e-05	0.000132	CbGpPWpGaD
Bosutinib—MAP3K7—Innate Immune System—KIT—testicular cancer	1.62e-05	0.000132	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—KITLG—testicular cancer	1.62e-05	0.000132	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—STK11—testicular cancer	1.62e-05	0.000132	CbGpPWpGaD
Bosutinib—EGFR—Axon guidance—MMP2—testicular cancer	1.62e-05	0.000132	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—FGFR3—testicular cancer	1.59e-05	0.000129	CbGpPWpGaD
Bosutinib—BTK—Immune System—KIT—testicular cancer	1.58e-05	0.000129	CbGpPWpGaD
Bosutinib—HCK—Immune System—FGFR3—testicular cancer	1.58e-05	0.000129	CbGpPWpGaD
Bosutinib—PTK2—Immune System—KITLG—testicular cancer	1.57e-05	0.000128	CbGpPWpGaD
Bosutinib—LCK—Immune System—BCL10—testicular cancer	1.57e-05	0.000128	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—KITLG—testicular cancer	1.56e-05	0.000127	CbGpPWpGaD
Bosutinib—MAP3K7—Adaptive Immune System—KIT—testicular cancer	1.55e-05	0.000127	CbGpPWpGaD
Bosutinib—YES1—Immune System—KITLG—testicular cancer	1.55e-05	0.000126	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—FGFR3—testicular cancer	1.54e-05	0.000126	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—KIT—testicular cancer	1.51e-05	0.000123	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—KIT—testicular cancer	1.51e-05	0.000123	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—FGFR3—testicular cancer	1.5e-05	0.000123	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—KITLG—testicular cancer	1.5e-05	0.000122	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—FGFR3—testicular cancer	1.49e-05	0.000121	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—FGFR3—testicular cancer	1.47e-05	0.00012	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—KITLG—testicular cancer	1.47e-05	0.00012	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—FGFR3—testicular cancer	1.47e-05	0.000119	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—FGFR3—testicular cancer	1.46e-05	0.000119	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—KIT—testicular cancer	1.46e-05	0.000119	CbGpPWpGaD
Bosutinib—HCK—Disease—FGFR3—testicular cancer	1.46e-05	0.000119	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—FGFR3—testicular cancer	1.45e-05	0.000118	CbGpPWpGaD
Bosutinib—HCK—Immune System—KIT—testicular cancer	1.45e-05	0.000118	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—FGFR3—testicular cancer	1.44e-05	0.000118	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—FGFR3—testicular cancer	1.44e-05	0.000118	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—KITLG—testicular cancer	1.44e-05	0.000117	CbGpPWpGaD
Bosutinib—BLK—Immune System—FGFR3—testicular cancer	1.43e-05	0.000117	CbGpPWpGaD
Bosutinib—FGR—Immune System—FGFR3—testicular cancer	1.42e-05	0.000116	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—MMP2—testicular cancer	1.42e-05	0.000116	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—KIT—testicular cancer	1.41e-05	0.000115	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—FGFR3—testicular cancer	1.41e-05	0.000115	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—H2AFZ—testicular cancer	1.41e-05	0.000115	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—FGFR3—testicular cancer	1.4e-05	0.000114	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—STK11—testicular cancer	1.4e-05	0.000114	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—FGFR3—testicular cancer	1.39e-05	0.000113	CbGpPWpGaD
Bosutinib—SRC—Immune System—BCL10—testicular cancer	1.39e-05	0.000113	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—H2AFZ—testicular cancer	1.38e-05	0.000113	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—KITLG—testicular cancer	1.38e-05	0.000113	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—KIT—testicular cancer	1.38e-05	0.000113	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—KITLG—testicular cancer	1.38e-05	0.000113	CbGpPWpGaD
Bosutinib—SRC—Axon guidance—MMP2—testicular cancer	1.38e-05	0.000112	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—STK11—testicular cancer	1.38e-05	0.000112	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—FGFR3—testicular cancer	1.38e-05	0.000112	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—FGFR3—testicular cancer	1.38e-05	0.000112	CbGpPWpGaD
Bosutinib—ERBB4—Disease—FGFR3—testicular cancer	1.37e-05	0.000112	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—KIT—testicular cancer	1.36e-05	0.000111	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—MMP2—testicular cancer	1.36e-05	0.000111	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—KIT—testicular cancer	1.35e-05	0.00011	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—MMP2—testicular cancer	1.35e-05	0.00011	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—KIT—testicular cancer	1.35e-05	0.00011	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—KIT—testicular cancer	1.34e-05	0.00011	CbGpPWpGaD
Bosutinib—HCK—Disease—KIT—testicular cancer	1.34e-05	0.000109	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—MMP2—testicular cancer	1.34e-05	0.000109	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—H2AFZ—testicular cancer	1.33e-05	0.000109	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—KIT—testicular cancer	1.33e-05	0.000108	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—FGFR3—testicular cancer	1.33e-05	0.000108	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—MMP2—testicular cancer	1.33e-05	0.000108	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—STK11—testicular cancer	1.33e-05	0.000108	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—KIT—testicular cancer	1.33e-05	0.000108	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—KIT—testicular cancer	1.32e-05	0.000108	CbGpPWpGaD
Bosutinib—BLK—Immune System—KIT—testicular cancer	1.31e-05	0.000107	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—FGFR3—testicular cancer	1.31e-05	0.000107	CbGpPWpGaD
Bosutinib—FGR—Immune System—KIT—testicular cancer	1.31e-05	0.000107	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—KIT—testicular cancer	1.3e-05	0.000106	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—KITLG—testicular cancer	1.29e-05	0.000105	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—KIT—testicular cancer	1.29e-05	0.000105	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—H2AFZ—testicular cancer	1.29e-05	0.000105	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—H2AFZ—testicular cancer	1.29e-05	0.000105	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—KIT—testicular cancer	1.28e-05	0.000104	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—STK11—testicular cancer	1.28e-05	0.000104	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—STK11—testicular cancer	1.28e-05	0.000104	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—KITLG—testicular cancer	1.27e-05	0.000104	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—KIT—testicular cancer	1.26e-05	0.000103	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—KIT—testicular cancer	1.26e-05	0.000103	CbGpPWpGaD
Bosutinib—ERBB4—Disease—KIT—testicular cancer	1.26e-05	0.000103	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—FGFR3—testicular cancer	1.25e-05	0.000102	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—H2AFZ—testicular cancer	1.24e-05	0.000101	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—STK11—testicular cancer	1.23e-05	0.0001	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—KITLG—testicular cancer	1.23e-05	0.0001	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—KIT—testicular cancer	1.22e-05	9.95e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—H2AFZ—testicular cancer	1.21e-05	9.88e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—FGFR3—testicular cancer	1.21e-05	9.86e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—KITLG—testicular cancer	1.21e-05	9.84e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—FGFR3—testicular cancer	1.21e-05	9.84e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—KIT—testicular cancer	1.2e-05	9.8e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—FGFR3—testicular cancer	1.2e-05	9.8e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—H2AFZ—testicular cancer	1.18e-05	9.64e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—KITLG—testicular cancer	1.18e-05	9.64e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—KITLG—testicular cancer	1.18e-05	9.64e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—KITLG—testicular cancer	1.18e-05	9.61e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—FGFR3—testicular cancer	1.17e-05	9.5e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—FGFR3—testicular cancer	1.16e-05	9.45e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—KITLG—testicular cancer	1.15e-05	9.4e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—MMP2—testicular cancer	1.15e-05	9.4e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—FGFR3—testicular cancer	1.15e-05	9.37e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—KIT—testicular cancer	1.15e-05	9.37e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—KITLG—testicular cancer	1.15e-05	9.36e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—H2AFZ—testicular cancer	1.14e-05	9.29e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—KITLG—testicular cancer	1.14e-05	9.29e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—KITLG—testicular cancer	1.14e-05	9.26e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—H2AFZ—testicular cancer	1.13e-05	9.24e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—KITLG—testicular cancer	1.13e-05	9.21e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—KITLG—testicular cancer	1.11e-05	9.09e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—FGFR3—testicular cancer	1.11e-05	9.06e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—KIT—testicular cancer	1.11e-05	9.05e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—KIT—testicular cancer	1.11e-05	9.03e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—KIT—testicular cancer	1.1e-05	9e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—H2AFZ—testicular cancer	1.1e-05	8.99e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—STK11—testicular cancer	1.1e-05	8.94e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—FGFR3—testicular cancer	1.09e-05	8.89e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—KITLG—testicular cancer	1.09e-05	8.87e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—H2AFZ—testicular cancer	1.09e-05	8.86e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—STK11—testicular cancer	1.08e-05	8.81e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—KIT—testicular cancer	1.07e-05	8.73e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—FGFR3—testicular cancer	1.07e-05	8.71e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—KIT—testicular cancer	1.06e-05	8.67e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—KIT—testicular cancer	1.06e-05	8.61e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—KITLG—testicular cancer	1.05e-05	8.55e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KITLG—testicular cancer	1.04e-05	8.5e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—H2AFZ—testicular cancer	1.03e-05	8.41e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—FGFR3—testicular cancer	1.03e-05	8.37e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—FGFR3—testicular cancer	1.03e-05	8.36e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—STK11—testicular cancer	1.03e-05	8.36e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—KIT—testicular cancer	1.02e-05	8.32e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KITLG—testicular cancer	1.01e-05	8.27e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—KIT—testicular cancer	1e-05	8.16e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KITLG—testicular cancer	1e-05	8.15e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—H2AFZ—testicular cancer	9.85e-06	8.03e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—MMP2—testicular cancer	9.84e-06	8.02e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KITLG—testicular cancer	9.81e-06	8e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—KIT—testicular cancer	9.81e-06	7.99e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—H2AFZ—testicular cancer	9.71e-06	7.92e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—STK11—testicular cancer	9.65e-06	7.87e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—FGFR3—testicular cancer	9.61e-06	7.83e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—H2AFZ—testicular cancer	9.49e-06	7.74e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KITLG—testicular cancer	9.49e-06	7.73e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—FGFR3—testicular cancer	9.47e-06	7.72e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—KITLG—testicular cancer	9.46e-06	7.71e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—KIT—testicular cancer	9.43e-06	7.69e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—KIT—testicular cancer	9.42e-06	7.68e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—FGFR3—testicular cancer	9.12e-06	7.43e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—KITLG—testicular cancer	9.06e-06	7.39e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—FGFR3—testicular cancer	8.97e-06	7.32e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KITLG—testicular cancer	8.93e-06	7.28e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—KIT—testicular cancer	8.82e-06	7.19e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—FGFR3—testicular cancer	8.79e-06	7.16e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—FGFR3—testicular cancer	8.79e-06	7.16e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—FGFR3—testicular cancer	8.76e-06	7.14e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—KITLG—testicular cancer	8.73e-06	7.12e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—KIT—testicular cancer	8.69e-06	7.09e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—FGFR3—testicular cancer	8.57e-06	6.99e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—FGFR3—testicular cancer	8.53e-06	6.96e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—H2AFZ—testicular cancer	8.49e-06	6.92e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—FGFR3—testicular cancer	8.47e-06	6.9e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—FGFR3—testicular cancer	8.44e-06	6.88e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STK11—testicular cancer	8.44e-06	6.88e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—H2AFZ—testicular cancer	8.4e-06	6.85e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—FGFR3—testicular cancer	8.4e-06	6.84e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—KIT—testicular cancer	8.37e-06	6.83e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—KITLG—testicular cancer	8.37e-06	6.82e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—FGFR3—testicular cancer	8.29e-06	6.75e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—H2AFZ—testicular cancer	8.28e-06	6.75e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—KIT—testicular cancer	8.24e-06	6.72e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STK11—testicular cancer	8.23e-06	6.71e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—H2AFZ—testicular cancer	8.11e-06	6.61e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—FGFR3—testicular cancer	8.09e-06	6.59e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—KIT—testicular cancer	8.07e-06	6.58e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—KIT—testicular cancer	8.07e-06	6.58e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STK11—testicular cancer	8.06e-06	6.57e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—KIT—testicular cancer	8.04e-06	6.55e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—H2AFZ—testicular cancer	7.98e-06	6.51e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—H2AFZ—testicular cancer	7.94e-06	6.47e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STK11—testicular cancer	7.94e-06	6.47e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STK11—testicular cancer	7.89e-06	6.43e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—KIT—testicular cancer	7.87e-06	6.42e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—KIT—testicular cancer	7.84e-06	6.39e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KITLG—testicular cancer	7.81e-06	6.36e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—FGFR3—testicular cancer	7.79e-06	6.35e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—KIT—testicular cancer	7.78e-06	6.34e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—FGFR3—testicular cancer	7.75e-06	6.32e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—KIT—testicular cancer	7.75e-06	6.32e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—KITLG—testicular cancer	7.73e-06	6.3e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—KIT—testicular cancer	7.71e-06	6.28e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KITLG—testicular cancer	7.62e-06	6.21e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—KIT—testicular cancer	7.61e-06	6.2e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—FGFR3—testicular cancer	7.54e-06	6.15e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KITLG—testicular cancer	7.46e-06	6.08e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—FGFR3—testicular cancer	7.43e-06	6.06e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—KIT—testicular cancer	7.42e-06	6.05e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KITLG—testicular cancer	7.34e-06	5.99e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KITLG—testicular cancer	7.3e-06	5.95e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—FGFR3—testicular cancer	7.29e-06	5.94e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—KIT—testicular cancer	7.16e-06	5.83e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KIT—testicular cancer	7.12e-06	5.8e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—FGFR3—testicular cancer	7.05e-06	5.75e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—FGFR3—testicular cancer	7.03e-06	5.73e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KIT—testicular cancer	6.92e-06	5.64e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—H2AFZ—testicular cancer	6.9e-06	5.62e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STK11—testicular cancer	6.86e-06	5.59e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KIT—testicular cancer	6.83e-06	5.56e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—FGFR3—testicular cancer	6.73e-06	5.49e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KIT—testicular cancer	6.7e-06	5.46e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—H2AFZ—testicular cancer	6.65e-06	5.42e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—FGFR3—testicular cancer	6.64e-06	5.41e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STK11—testicular cancer	6.61e-06	5.39e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—FGFR3—testicular cancer	6.49e-06	5.29e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KIT—testicular cancer	6.47e-06	5.28e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—KIT—testicular cancer	6.45e-06	5.26e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KITLG—testicular cancer	6.34e-06	5.17e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—FGFR3—testicular cancer	6.22e-06	5.07e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—KIT—testicular cancer	6.18e-06	5.04e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KITLG—testicular cancer	6.11e-06	4.98e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KIT—testicular cancer	6.1e-06	4.97e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—KIT—testicular cancer	5.96e-06	4.86e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—H2AFZ—testicular cancer	5.88e-06	4.8e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STK11—testicular cancer	5.85e-06	4.77e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—FGFR3—testicular cancer	5.8e-06	4.73e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—FGFR3—testicular cancer	5.74e-06	4.68e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—KIT—testicular cancer	5.71e-06	4.66e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—HPGDS—testicular cancer	5.7e-06	4.64e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—FGFR3—testicular cancer	5.66e-06	4.62e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—FGFR3—testicular cancer	5.54e-06	4.52e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—FGFR3—testicular cancer	5.46e-06	4.45e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—FGFR3—testicular cancer	5.43e-06	4.43e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KITLG—testicular cancer	5.41e-06	4.41e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KIT—testicular cancer	5.33e-06	4.34e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—KIT—testicular cancer	5.27e-06	4.3e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KIT—testicular cancer	5.2e-06	4.24e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KIT—testicular cancer	5.09e-06	4.15e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KIT—testicular cancer	5.01e-06	4.08e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KIT—testicular cancer	4.98e-06	4.06e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—FGFR3—testicular cancer	4.71e-06	3.84e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—FGFR3—testicular cancer	4.54e-06	3.7e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KIT—testicular cancer	4.33e-06	3.53e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KIT—testicular cancer	4.17e-06	3.4e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—STK11—testicular cancer	4.14e-06	3.37e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGFR3—testicular cancer	4.02e-06	3.28e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KIT—testicular cancer	3.69e-06	3.01e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HPGDS—testicular cancer	3.51e-06	2.86e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—STK11—testicular cancer	2.55e-06	2.08e-05	CbGpPWpGaD
